Navigation Links
Stephens Initiates Coverage on Vermillion
Date:3/25/2011

AUSTIN, Texas, March 25, 2011 /PRNewswire/ -- (Nasdaq: VRML) – Vermillion, a molecular diagnostics company, announced today that Stephens, Inc. initiated analyst coverage March 23, 2011 on Vermillion.

This research report may be obtained directly from the analyst at Stephens by contacting, Scott Gleason at scott.gleason@stephens.com.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found on the Web at www.vermillion.com.

About OVA1®

OVA1® is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta 2-Microglobulin (Beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned. Additional information about OVA1® can be found on the Web at www.ova-1.com.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's pl
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genomic Health to Present at Stephens Fall Investment Conference
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , Shareholders ... , Call by over 18% of ... Significant funding shortfall identified in the Progen merger proposal , ... Late last week Progen Pharmaceuticals Limited (ASX: PGL) responded to the requisitioning ...
... Clinics of Excellence, LLC, the nation,s only physician-driven ... its 62nd comprehensive Evidence-Based Treatment Protocol covering 11 ... 4th Annual Community Oncology Conference today. "Our 200+ ... to launch the protocols across its network in ...
... Feb. 6 Stereotaxis, Inc. (Nasdaq:, STXS ) ... for the,fourth quarter and full year ended December 31, ... The Company will host a conference call and,webcast on ... to discuss,the Company,s fourth quarter results and current corporate ...
Cached Biology Technology:Cytopia and Other Progen Shareholders Maintain Call for Meeting 2Cytopia and Other Progen Shareholders Maintain Call for Meeting 3Cytopia and Other Progen Shareholders Maintain Call for Meeting 4Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol 2Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2
(Date:12/22/2014)... Research and Markets ( ... the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 ... the global digital media watermarking and fingerprinting ... piracy by securely and invisibly embedding identifiable ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... X syndrome (FXS) is the most common hereditary form ... from attention deficit and/or hyperactivity disorder (ADHD), which complicates ... medication such as Ritalin is often successfully used to ... it is effective in children with mental retardation, it ...
... choose the nesting location of their first breeding season has ... a new University of Maryland/National Zoo study of the ... in their first year may help determine where they breed ... significantly affect the population as climate change makes their winter ...
... January 2001, the world held its breath when the tanker ... and began breaking up in the heart of one of ... the Galapagos Islands. At risk were vast numbers of ... Charles Darwin that contributed to his landmark theory of evolution ...
Cached Biology News:Effective ADHD treatment found for children with fragile X syndrome 2Early environment may be key to determining bird migration location 2Early environment may be key to determining bird migration location 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4
Standard Fluka For microscopy (Bact., Hist.)...
Request Info...
... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
Special grade: for electrophoresis...
Biology Products: